AstraZeneca
NEWS
The newly-launched index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative pharmaceutical pipelines.
Thanks to a new regulatory win, AstraZeneca’s Farxiga can now be used to reduce the risk of hospitalization for heart failure in type 2 diabetes patients with cardiovascular disease and with certain risk factors.
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
It was another busy week for clinical trials. Here’s a look.
The approval was based on data from the Phase III GRECO clinical trial and the Phase I AMES trial.
The U.S. Food and Drug Administration (FDA) rejected the company’s inhaled triple-combination therapy, PT010, now known as Breztri Aerosphere.
PARP inhibitors will be taking center stage at the European Society of Medical Oncology Congress as rival drugmakers aim to show off data that supports broader use of the drug in treating various cancers.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
JOBS
IN THE PRESS